Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

6 Nov 2023

Abstract excerpt

Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma (MM). Over the years, BCL-2, a crucial anti-apoptotic protein, has garnered significant attention in MM therapeutic research. Venetoclax (VTC), a small-molecule targeted agent, effectively inhibits BCL-2, promoting the programmed death of cancerous cells. While VTC has been employed to treat various hematological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38026941
DOI: 10.3389/fphar.2023.1291920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature reviewPMID 38026941Read ↗

Targeting Bcl-2 for the treatment of multiple myeloma.Semantic proximity Read ↗

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma ModelsSemantic proximity Read ↗

The rise of apoptosis: targeting apoptosis in hematologic malignanciesSemantic proximity Read ↗

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexesSemantic proximity Read ↗

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatmentSemantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

BCL2 and MCL1 inhibitors for hematologic malignanciesSemantic proximity Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy BiomarkerSemantic proximity Read ↗

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity Read ↗

Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaSemantic proximity Read ↗

Targeting Bcl-2 Proteins in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.